Skip to content
Open Imaging Index
LicenseRef-DIAN-TU-Sharing-Policy ยท custom agreement

DIAN-TU Data and Biospecimen Sharing, Publication, Authorship and Citation Policies

Qualified researchers get de-identified trial data for research approved by DIAN-TU, with Industry Collaborators able to review requests and manuscripts. Requires IRB or ethics documentation and a Data Use Agreement; no sharing with third parties; data destroyed after analysis; every publication or presentation is reviewed and approved by DIAN-TU first.

Original license text Edit Purpose: Approved project only Version read: Version 2.1, 20 July 2026 Checked 2026-10-08
GA4GH DUO: PSIRBTS

Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer

In your favor With conditions Restricts you Not stated in the text

What you can do

  • Not stated
  • Not stated
  • Not stated
  • Conditional
  • Conditional

What you can share

  • No
  • Not stated
  • Share trained models Not stated

What you must do

  • Yes
  • Share alike No
  • Yes
  • Yes
  • Yes
  • Conditional
  • Conditional
  • Yes

Limits

  • Yes
  • No

Datasets under this license

  • DIAN-TU-001 (gantenerumab and solanezumab arms)

    Frequent safety brain MRI read for amyloid-related imaging abnormalities (ARIA), amyloid PET, CSF and cognition from a placebo-controlled trial of gantenerumab or solanezumab in carriers of inherited Alzheimer's mutations. 142 participants in the first two drug arms.